Smart combo attack: new trial matches lung cancer drugs to tumor fingerprints
NCT ID NCT07172412
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This phase 2 trial is testing several drug combinations as a first treatment for extensive-stage small cell lung cancer. Researchers will assign 165 participants to different treatment arms based on specific biomarkers in their tumors. The goal is to see if matching therapy to these markers improves outcomes like tumor shrinkage and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 300060
Tianjin, Tianjin Municipality, China
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selinexor, Anlotinib, DLL3 CAR-NK cells, Etoposide + Cisplatin/Carboplatin, and immunotherapies (Tislelizumab, Atezolizumab, Durvalumab, Benmelstobart, Toripalimab, Serplulimab)
What this could lead to
If successful, this could point toward more personalized, effective first-line treatments for extensive-stage small cell lung cancer, potentially improving survival and quality of life.
What could go wrong
This is an early-phase (2) trial with a small sample size (165), so results may not apply broadly. Combination therapies also carry higher risks of side effects, and the experimental arms may not outperform standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.